P ulmonary arterial hypertension (PAH) is a fatal and progressive disease characterized by elevated pulmonary vascular resistance resulting from severe pulmonary vascular remodeling. [1] [2] [3] Approximately 6% of PAH patients have a family history of the condition and are referred to as having familial PAH; the rest are considered to have idiopathic PAH (IPAH). Although the cause of PAH remains unclear, elevated levels of mitogenic, angiogenic, and proinflammatory factors such as platelet-derived growth factor, endothelin-1, interleukin-1␤/-6, soluble CD40 ligand, angiopoietin-1, and serotonin have been reported to correlate with the onset of IPAH. [2] [3] [4] Other factors associated with IPAH include the downregulation and dysfunction of voltage-gated K ϩ channels 5 and upregulation of the serotonin receptors and transporter. 6 Moreover, mutations in the bone morphogenetic protein receptor-type II gene (BMPR2) have been demonstrated to associate with the development of familial PAH and IPAH. 7, 8 However, because BMPR2 mutations are present in only 15% to 20% of IPAH patients and the likelihood that clinical pulmonary hypertension will develop is only 10% to 20% in known carriers of BMPR2 mutations, 9 additional genetic and environmental factors other than BMPR2 mutations may also contribute to the development of IPAH.
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Regardless of the initial pathogenic trigger, the elevated pulmonary vascular resistance and pulmonary arterial pressure in IPAH patients are caused mainly by sustained pulmonary vasoconstriction, concentric vascular remodeling, obliteration of small arteries and arterioles, in situ thrombosis, and formation of the plexiform lesion. [1] [2] [3] Neointimal and medial hypertrophy in small and medium-sized pulmonary arteries is a key aspect of pulmonary vascular remodeling in IPAH patients and is attributed to excessive pulmonary artery smooth muscle cell (PASMC) proliferation. 1, 2 Ca 2ϩ operates as an important second messenger in cellular mechanisms leading to gene expression, cell proliferation, and contraction. A rise in cytosolic free Ca 2ϩ concentration ([Ca 2ϩ ] cyt ) in PASMCs is a major trigger for pulmonary vasoconstriction and an important stimulus for PASMC proliferation and migration. 10 Conventional Ca 2ϩ channel blockers (ie, nifedipine and diltiazem), which inhibit voltagedependent Ca 2ϩ channels in PASMCs, have been used to treat 15% to 20% of IPAH patients in clinical studies, 11 suggesting that increased [Ca 2ϩ ] cyt may be an important link in cellular pathways that lead to IPAH. Elevation of [Ca 2ϩ ] cyt in PASMCs results from Ca 2ϩ release from intracellular stores and Ca 2ϩ influx through plasmalemmal Ca 2ϩ channels. 12 In addition to voltage-dependent Ca 2ϩ channels, it has been demonstrated that canonical transient receptor potential (TRPC) channels are responsible for Ca 2ϩ entry in PASMCs. [12] [13] [14] TRPC6 is an important isoform of TRPC channels expressed in the lungs and pulmonary artery. [12] [13] [14] [15] We previously observed that TRPC6 mRNA and protein expression in lung tissues and PASMCs isolated from IPAH patients was substantially elevated compared with normal subjects and control patients with cardiopulmonary diseases. 16 TRPC6 upregulation is also a critical initial step in the elevation of [Ca 2ϩ ] cyt required for mitogen-mediated PASMC proliferation and a critical contributor to the elevated [Ca 2ϩ ] cyt in IPAH PASMCs. 13 Downregulation of TRPC6 expression with siRNA significantly attenuates DNA synthesis and proliferation of PASMCs isolated from normotensive and IPAH patients. 13, 16 Together, these observations imply that upregulated TRPC6 gene transcription may promote the development of IPAH. 17 To test this hypothesis, we sequenced the 5Ј-regulatory region of TRPC6 from 268 IPAH patients and identified a C to G (C3 G) single-nucleotide polymorphism (SNP) at nucleotide Ϫ254 of the TRPC6 gene that is associated with IPAH. Moreover, the Ϫ254C3 G change creates a canonical nuclear factor-B (NF-B) binding site (GGGGGTCTCC) in the promoter region of TRPC6 and significantly affects TRPC6 gene transcription and TRPC6 channel function in PASMCs from IPAH patients who carry the Ϫ254G allele.
Methods

Subjects
A total of 237 normal subjects and 268 IPAH patients (including 124 patients enrolled at the University of California, San Diego Medical Center, 60 patients at the Vanderbilt University Medical Center, and 84 patients in the Giessen Lung Center in Germany) who participated in the study. All control subjects (all white) and IPAH patients were white (including 2 Hispanics) and were unrelated. The control subjects and patients were very closely matched racially and ethnically. We did not include data from blacks in this report because of the small sample number. The basic demographics of age, gender, and race in normal subjects and IPAH patients and the hemodynamics of all patients from each of the 3 centers are shown in Table I of the online-only Data Supplement. No significant difference was found (Pϭ0.68682) between normal subjects (87.7Ϯ9. 35 [SD] mm Hg) and IPAH patients (88.3Ϯ14.76 mm Hg) from whom we collected blood/ DNA samples for this study. The diagnosis of IPAH was based on the criteria used in the National Institutes of Health Registry on Primary Pulmonary Hypertension. Informed consent was obtained from all subjects, and the study was approved by the Institutional Review Board at the University of California, San Diego.
Identification of SNP in the TRPC6 Gene Promoter Region
Genomic DNA was extracted from the blood samples of normal subjects and patients with a Wizard genomic DNA purification kit. Six paired amplification polymerase chain reaction (PCR) primers (online-only Data Supplement Table II) were designed to amplify 6 overlapping DNA segments spanning 2000 bp upstream and 110 bp downstream of the transcriptional start site of human TRPC6. The purified PCR products were sequenced, analyzed by Chromas software, and compared with known SNPs deposited in the NCBI SNP databank (see supplementary Materials).
Cell Preparation and Culture
PASMCs from IPAH patients and non-pulmonary hypertensive (NPH) patients were isolated from lung tissues of transplant patients, and PASMCs from normal subjects were purchased from Lonza (Walkersville, Md). PASMCs were cultured in 5% CO 2 in air at 37°C in smooth muscle cell growth medium (Lonza) and used at the fourth to sixth passage. 5, 12 For tumor necrosis factor-␣ (TNF-␣) stimulation experiments, the cells were growth arrested by culturing in smooth muscle cell basal medium (Lonza) for 24 hours before treatment.
Preparation of Cytoplasmic and Nuclear Extracts
Cytosolic and nuclear extracts from cultured PASMCs were collected using a modified protocol 18 (see supplementary Materials).
Electrophoretic Mobility Shift Assay and Supershift Assay
Double-stranded oligonucleotide sequences from nucleotide Ϫ261 to Ϫ238 of TRPC6 containing the Ϫ254C wild-type (5Ј-ATCCTCGCGGGGTCTCCTCGGCCT-3Ј) or Ϫ254G mutated site (5Ј-ATCCTCGGGGGGTCTCCTCGGCCT-3Ј) were synthesized and labeled by the biotin 3Ј end-labeling kit (Pierce Biotechnology Inc, Rockford, Ill). Each binding reaction (24°C for 40 minutes) contained 10 mmol/L Tris (pH 7.5), 50 mmol/L KCl, 1 mmol/L EDTA, 10 mmol/L dithiothreitol, 2.5% glycerol, 50 ng/mL poly(dIdC), 5% albumin bovine, 4 g nuclear extract, and 40 to 50 fmol biotin end-labeled target DNA. Competition tests were used to verify whether the observed shifted bands were specific. The nuclear extract was preincubated with 200-fold excess unlabeled Ϫ254C or Ϫ254G probe before electrophoretic mobility shift assay. For supershift assays, polyclonal antibodies against p50 or p65 were added to the binding reaction before addition of the biotin end-labeled probe. The DNA-protein complexes were electrophoresed by 6% DNA retardation gels in 0.5ϫ TBE running buffer and electrotransferred to nitrocellulose membranes. The biotin-labeled oligonucleotides in the membrane were detected with streptavidin-horseradish peroxidase conjugate and a chemiluminescent substrate (Pierce).
TRPC6 Putative Promoter Region Cloning and Promoter Activity
The human TRPC6 putative promoter regions were amplified using genomic DNA isolated from PASMCs. The DNA fragments (Ϫ1682 to 110 bp) containing Ϫ254C or Ϫ254G were amplified by PCR. The PCR products were cloned into PCR 2.1 TOPO cloning vector. A transient expression system, pBlue-TOPO TA expression kit, was used to test the cloned TRPC6 putative promoter activities. DNA fragments were fused to the promoterless ␤-glucuronidase (LacZ) reporter gene vector. COS-7 cells were transiently transfected with promoter vectors and, 24 hours after transfection, replated onto Petri dishes coated with poly-L-lysine. The promoter activities were detected and quantified by measuring the absorbance at 420 nm. Transfection efficiencies were normalized to green fluorescence protein (GFP) expression from a cotransfected pRL-CMV-GFP vector. The relative promoter activity is expressed as fold induction relative to the basal level of promoterless empty pBlue-TOPO vector. For LacZ staining, the cells were fixed with 0.05% glutaraldehyde and stained in X-Gal solution containing 40 mmol/L HEPES (pH 7. 6 ], 2 mmol/L MgCl 2 , 15 mmol/L NaCl, and 1 mg/mL X-Gal.
Generation of Recombinant Adenovirus Carrying Human TRPC6-Specific siRNA and Adenoviral Infection
Recombinant adenovirus carrying siRNA targeting human TRPC6 was generated with an Invitrogen expression kit (Invitrogen, Carlsbad, Calif). For adenovirus infection experiments, PASMCs were infected with the appropriate virus in smooth muscle cell basal medium containing 0.2% FBS for 4 hours and used for experiments 24 to 48 hours after adenoviral infection (see supplementary Materials).
Human TRPC6 cDNA Cloning and Transient Transfection
Human TRPC6 cDNA was purchased from Open Biosystems (Huntsville, Ala). It was tagged with a hemagglutinin HA epitope sequence at the C terminal by introducing an in-frame HA epitope coding sequence before the stop codon and subcloning the corresponding cDNA into a mammalian expression pCDNA3 vector (Invitrogen) and pCMS-EGFP vector (BD Bioscience, San Jose, Calif), respectively. Resulting clones were confirmed by DNA sequencing and were designated pcDNA3-hTRPC6
HA and pCMS-EGFP-hTRPC6
HA . For transient transfection, electroporationmediated transfection by nucleofector (Amaxa Biosystems, Walkersville, Md) was used, following the PASMC-specific protocol. 
Statistical Analysis
Values are expressed as meanϮSEM. Statistical differences were assessed with unpaired Student t test or 1-way ANOVA with post hoc analysis. Differences were considered significant at values of PϽ0.05. We used 2 analysis to compare the allele frequencies and genotype frequencies in normal subjects and patients. The odds ratio was estimated by the logistic regression model, assuming 95% as the CI, using the Woolf approximation. StatsDirect software (StatsDirect, Ltd, Cheshire, UK) was used for this analysis.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Three SNPs Were Identified in the Putative Promoter Region of TRPC6
The human TRPC6 gene contains 13 exons ( Figure 1A ). Using specifically designed primers, we sequenced the 5Ј-untranslated region (Ϫ2000 bp upstream of the start codon, ATG) of TRPC6 ( Figure 1B ) from 237 normal subjects and 268 IPAH patients. DNA sequence alignment with the human genomic TRPC6 sequence (AP003080) revealed 3 variants, Ϫ361(A3 T), Ϫ254(C3 G), and Ϫ218(C3 T) ( Figure 1B and 1C) . All 3 SNPs have been reported and are listed in the NCBI SNP database: Ϫ254(C3 G) SNP matches to rs3824934, Ϫ361(A3 T) to rs41302375, and Ϫ218(C3 T) to rs56134796. The Ϫ361(A3 T) and Ϫ218(C3 T) SNPs are in complete linkage disequilibrium.
Allele and Genotype Frequencies of the ؊254C3 G SNP in TRPC6 Are Significantly Higher in IPAH Patients Than in Normal Subjects
To examine whether the 3 SNPs of TRPC6 are associated with IPAH, we analyzed their allele frequencies and genotype frequencies in IPAH patients and normal control subjects. As shown in Table 1 , the allele frequency of the Ϫ254G SNP was significantly higher in IPAH patients (12%) than in normal subjects (6%; PϽ0.01), whereas the allele frequencies of the Ϫ361(A3 T) and Ϫ218(C3 T) SNPs were comparable (Pϭ0.83) between IPAH patients (25% and 25%) and normal subjects (25% and 25%). Both the homozygous and heterozygous variants of the Ϫ254(C3 G) SNP were identified in IPAH patients ( Figure 1C ). Genotype analysis showed that 25 of 237 normal subjects (10.5%) were heterozygotes and 3 of 237 of normal subjects (1.3%) were homozygotes for the Ϫ254(C3 G) SNP. In contrast, 43 of 268 of the IPAH patients (16.0%) were heterozygotes (Ϫ254C/G) and 10 of 268 patients (3.7%) were homozygotes (Ϫ254G/G) (PϽ0.02 between normal subjects and IPAH patients for both heterozygotes and homozygotes; Table 2 ). The Ϫ254C/G heterozygote and Ϫ254G/G homozygote frequencies in IPAH patients were 1.52 (16.0% versus 10.5%) and 2.85 (3.7% versus 1.3%) times, respectively, those of normal subjects (PϽ0.02). A full description of the allele frequencies for each patient cohort is provided in online-only Data Supplement Table III .
The ؊254(C3 G) SNP Generates an NF-B Binding Site at the Promoter Region of TRPC6
Interestingly, the C-to-G conversion at nucleotide Ϫ254 results in the sequence alteration of "CGGGGTCTCC" (nucleotide Ϫ254 to Ϫ245) to "GGGGGTCTCC," which matches the sequence of "GGGRNNYYCC" (where RϭA or G; YϭC or T; Nϭany nucleotide), a consensus sequence for the transcription factor NF-B. Therefore, the Ϫ254(C3 G) SNP adds a putative NF-B binding site into the 5Ј-untranslated region of TRPC6.
We performed an electrophoretic mobility shift assay to determine whether the Ϫ254(C3 G) SNP confers functional NF-B protein binding to the promoter region of TRPC6. Biotin-labeled oligoduplex probes with nucleotides encompassing sequences between nucleotide Ϫ238 and Ϫ261 containing Ϫ254C (Ϫ254C probe) or Ϫ254G (Ϫ254G probe) were incubated with nuclear extracts isolated from normal PASMCs. To evaluate the physiological or functional consequences, PASMCs were stimulated with TNF-␣ before the electrophoretic mobility shift assay was performed. As shown in Figure 2A , TNF-␣ (10 ng/mL) stimulated translocation of the p50 and p65 of the NF-B components into the nucleus of PASMCs, indicating that TNF-␣ is an effective stimulator for nuclear translocation of NF-B.
Two DNA-bound NF-B complexes were identified with the Ϫ254G probe (designated C1 and C2), whereas NF-B did not bind to the Ϫ254C probe ( Figure 2B , left). Complex formation (as indicated by C1 and C2) was inhibited by the addition of excess unlabeled Ϫ254G probe but not by P values, odds ratios, and 95% CIs are calculated by 2 analysis for comparison of the genotype frequencies between IPAH patients and normal subjects.
*Odds ratio and P value for (Ϫ361 A/T and Ϫ361 T/T) vs Ϫ361A/A and for (Ϫ218 C/T and Ϫ218 T/T) vs Ϫ218C/C. †Odds ratio and P value for (Ϫ254 C/G and Ϫ254 G/G) vs Ϫ254 C/C. The Ϫ361(A3 T) and Ϫ218(C3 T) SNPs are in complete linkage disequilibrium. Because their allele frequencies, odds ratio, and P values are identical, only the Ϫ361A3 T SNP is shown for the sake of clarity.
unlabeled Ϫ254C probe because the unlabeled Ϫ254G probe competitively bound to the same DNA binding site as NF-B, whereas the unlabeled Ϫ254C probe failed to compete for binding to the NF-B binding site. These results indicate that NF-B specifically binds to the Ϫ254G probe ( Figure 2B , right). Supershifted complexes were detected by the addition of the anti-p65 or anti-p50 antibody to the binding reaction, indicating that the NF-B C1 and C2 complexes contain a p50/p65 heterodimer and a p50/p50 homodimer, respectively ( Figure 2C ).
The ؊254(C3 G) SNP Affects NF-B-Mediated TRPC6 Promoter Activity
Gene constructs were generated to define whether the Ϫ254(C3 G) SNP introduces an active NF-B-regulated PASMCs from normal subjects were stimulated with (ϩ) or without (Ϫ) TNF-␣ (10 ng/mL). B, Electrophoretic mobility shift assay and competition analysis. TNF-␣-stimulated nuclear extracts from PASMCs were incubated with biotin-labeled double-stranded oligonucleotides corresponding to the 24-bp sequences containing the wildtype Ϫ254C or mutant Ϫ254G probes. Nuclear extract/oligonucleotide complexes (C1 and C2) are indicated by arrows. C, Antibodymediated supershift assay. NF-B p50 and p65 antibodies identified complexes C1 as p50/p65 and C2 as p50/p50 NF-B-containing complexes.
promoter region in the TRPC6 gene. Three different-length constructs of the 5Ј upstream region of TRPC6 containing Ϫ254C or Ϫ254G were cloned and inserted into a promoterless pBlue-TOPO vector upstream of a ␤-glucuronidase (LacZ) reporter gene. The resulting constructs were designated pBlue(Ϫ335/ϩ110), pBlue(Ϫ456/ϩ110), and pBlue(Ϫ1682/ϩ110), respectively.
In COS-7 cells transiently transfected with these vectors, TNF-␣ (20 ng/mL for 24 hours), by causing nuclear translocation of NF-B (p65 and p50), significantly enhanced promoter activity for the constructs [pBlue(Ϫ335/ϩ110), PϽ0.001; pBlue(Ϫ456/ϩ110), PϽ0.001; pBlue(Ϫ1682/ ϩ110), Pϭ0.027] with the Ϫ254G mutation but negligibly affected promoter activity for the constructs with the Ϫ254C wild-type sequence ( Figure 3A) [Pϭ0.437 (Ϫ335/ϩ110), Pϭ0.889 (Ϫ456/ϩ110), Pϭ0.231 (Ϫ1682/ϩ110)]. Compared with cells transfected with promoterless pBlue-TOPO vector, the basal promoter activity (or the relative induction of ␤-galactosidase activity in cells not treated with TNF-␣) significantly increased when the 5Ј upstream region was extended from nucleotide Ϫ335 to Ϫ456 and Ϫ1682 in the wild-type Ϫ254C template ( Figure 3A ). X-Gal staining confirmed these results by exhibiting an intense staining corresponding to ␤-galactosidase in the endoplasmic reticulum with the Ϫ254G pBlue(Ϫ335/ϩ110) construct but not with the Ϫ254C construct ( Figure 3B ). Together, these data indicate that the Ϫ254(C3 G) SNP modulates TRPC6 gene promoter activity and enhances TNF-␣-and NF-B-mediated TRPC6 transcription. Figure 4B and 4C). The OAG-induced increase in whole-cell cation currents in IPAH PASMCs was also significantly enhanced compared with normal PASMCs ( Figure 4D ). Inhibition of TRPC6 expression in IPAH PASMCs using siRNA markedly attenuated the OAG-mediated increase in [Ca 2ϩ ] cyt (PϽ0.001) and reduced the resting [Ca 2ϩ ] cyt (Pϭ0.003; Figure 5 ). In normal PASMCs (with the Ϫ254C/C genotype), overexpression of the human TRPC6 gene significantly enhanced the OAG-induced increase in [Ca 2ϩ ] cyt (PϽ0.001; Figure 6 ) but not resting [Ca 2ϩ ] cyt (Pϭ0.075). These results indicate that upregulated TRPC6 expression is functionally involved in regulating resting [Ca 2ϩ ] cyt and agonist-mediated Ca 2ϩ entry in PASMCs from IPAH patients harboring the Ϫ254G allele.
Upregulated TRPC6 Expression Contributes to
Inhibition of NF-B Activity by IB␣ Attenuates TRPC6 Expression and Function in PASMCs From IPAH Patients With the ؊254G Allele
IB␣ is an inhibitory subunit of the NF-B complex that binds to p50/p65 and keeps the complex in the cytoplasm. IB␣ superrepressor is a nondegradable mutant dominantnegative variant of IB␣ that inhibits NF-B activation. 19 Overexpression of the IB␣ superrepressor with an adenovi- ral vector markedly inhibited translocation of p50 and p65 into the nucleus in PASMCs from IPAH patients (with the Ϫ254G allele) and significantly inhibited TNF-␣-mediated upregulation of TRPC6 ( Figure 7A ). Western blot analysis indicated 2 bands corresponding to TRPC6 protein, 1 at Ϸ110 kDa and the other at 130 kDa. The Ϸ110-kDa band reflects nascent TRPC6 early in the secretory pathway, whereas the 130-kDa band reflects complex-glycosylated TRPC6 that appears to maintain a relatively long half-life. 20 In IPAH PASMCs (Ϫ254G allele) treated with TNF-␣, inhibition of NF-B by overexpression of the IB␣ superrepressor predominantly downregulated the nascent core-glycosylated isoform (the Ϸ110-kDa band) of TRPC6 ( Figure 7A, right) , implying that the effect is due to a reduction in TRPC6 gene transcription. Together, these data support the contention that NF-B plays an important role in regulating TRPC6 gene transcription and expression in IPAH patients harboring the Ϫ254(C3 G) SNP. This finding is supported by similar assays performed in PASMCs from Ϫ254C/C IPAH. Unlike the Ϫ254C/G individuals, TRPC6 protein expression was not 
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significantly altered in Ϫ254C/C PASMCs treated with TNF-␣ (see online-only Data Supplement Figure I ). To determine whether the enhanced basal TRPC6 expression and TNF-␣-mediated TRPC6 upregulation in the Ϫ254C/G variant have functional significance, we compared the levels of resting [Ca 2ϩ ] cyt and OAG-induced Ca 2ϩ influx in unstimulated and TNF-␣-stimulated Ϫ254C/G PASMCs from IPAH patients to the levels in PASMCs from Ϫ254C/C normal subjects. As shown in Figure 7B and Figure 7B ) but not in normal PASMCs from Ϫ254C/C subjects (Pϭ0.424; Figure 7C ). Furthermore, overexpression of IB␣ abolished the TNF-␣-mediated increase in the resting [Ca 2ϩ ] cyt and enhancement of the OAG-mediated Ca 2ϩ influx (PϽ0.001) in PASMCs from Ϫ254C/G IPAH patients ( Figure 7B ). These results provide strong evidence that the Ϫ254(C3 G) SNP in the TRPC6 gene has functional significance in regulating basal [Ca 2ϩ ] cyt and agonist-mediated Ca 2ϩ entry in PASMCs.
Discussion
We report 4 primary findings in this study: (1) A "gain-infunction" Ϫ254(C3 G) SNP in TRPC6 is associated with IPAH; (2) the Ϫ254(C3 G) SNP generates an active NF-B binding site that regulates TRPC6 transcription; (3) nuclear translocation of NF-B upregulates TRPC6 expression and enhances agonist-induced Ca 2ϩ influx in IPAH PASMCs with the Ϫ254G allele; and (4) inhibition of nuclear translocation of NF-B attenuates TRPC6 expression and function in PASMCs from IPAH patients harboring a Ϫ254G allele.
Pulmonary arterial neointimal and medial hypertrophy is a major pathological feature in IPAH. [1] [2] [3] One of the important mechanisms in pulmonary vascular wall thickening is increased PASMC proliferation and migration resulting from a rise in [Ca 2ϩ ] cyt . [12] [13] [14] [15] [16] As a critical signaling element, intracellular Ca 2ϩ is responsible for activating multiple signal transduction cascades that trigger PASMC contraction, activate gene expression, and stimulate PASMC proliferation. [12] [13] [14] [15] [16] 21 Upregulated TRPC6 plays an important role in the development of pulmonary vascular remodeling in IPAH patients. 16 TRPC6 is a canonical transient receptor potential channel isoform believed to be involved in forming receptor-operated Ca 2ϩ channels. 17, 22, 23 Studies on TRPC6 knockout mice revealed that TRPC6 plays a central role in receptor-operated control of vascular smooth muscle tone. 24 In cardiac myocytes, overexpressed TRPC6 plays an important role in forming a Ca 2ϩ -dependent calcineurin-NFAT-TRPC6 loop that leads to pathological cardiac hypertrophy and remodeling. 25 In PASMCs, TRPC6 is involved in forming functional Ca 2ϩ channels that are activated by vasoconstrictor and mitogenic factors. 13, 14, 26 Downregulation of TRPC6 inhibits PASMC proliferation. 13, 16 Compared with normal subjects and normotensive patients, mRNA and protein expression levels of TRPC6 in lung tissue and PASMCs were significantly higher in IPAH patients, suggesting an abnormal TRPC6 gene transcription in these patients. 16 In the present study, we found that the allele frequency of the Ϫ254(C3 G) SNP in TRPC6 was significantly higher in IPAH patients than in normal subjects. In contrast, the allele frequencies of the 2 neighboring SNPs, Ϫ361(A3 T) and Ϫ218(C3 T), were comparable between normal subjects and IPAH patients. Moreover, 3.7% of IPAH patients possess a homozygous Ϫ254G/G genotype, whereas 1.3% of the normal subjects have the homozygous Ϫ254G/G genotype. These data imply that the Ϫ254(C3 G) SNP may In addition, our observations showed that the Ϫ254(C3 G) SNP significantly increased the basal promoter activity of TRPC6 that is not related to NF-B. The increase in basal promoter activity occurred when the pBlue(Ϫ335/ϩ110) construct was used and was maintained when the pBlue(Ϫ456/ ϩ110) and pBlue(Ϫ1682/ϩ110) constructs were used. These results suggest that the Ϫ254(C3 G) SNP not only enhances NF-B-mediated TRPC6 transcription but also may enhance basal transcription of TRPC6 in PASMCs. Because many binding sites are present in the promoter region of TRPC6, it is possible that the Ϫ254G-generated NF-B binding site may facilitate interactions of various transcription factors (eg, NFAT, AP-1) to increase TRPC6 transcription. 25 The pathophysiological significance of insertion of an NF-B binding site into the TRPC6 gene may underlie the potential linkage of immune or inflammatory responses to the upregulation of TRPC6 channels in the pulmonary vasculature. The NF-B transcription factor family plays an essential role in immune and inflammatory responses and maintains an antiapoptotic function in normal and malignant cells. 28, 29 Given the fact that viral and bacterial infection, along with the inflammatory response resulting from the infection, is related to the development of the plexiform lesion and vascular remodeling in IPAH patients, 30 ,31 the Ϫ254(C3 G) SNP in TRPC6 may serve as an important genetic variation that links inflammatory response to the occurrence of IPAH and predisposes the Ϫ254G allele carriers to an increased risk for inflammation-mediated pulmonary arteriopathy. Furthermore, a potential exists that the Ϫ254(C3 G) SNP in TRPC6 may portend more importantly for patients with PAH secondary to connective tissue diseases (eg, scleroderma), HIV/AIDS, and schistosomiasis, who bear a significant inflammatory burden. Further study is needed to define whether the Ϫ254(C3 G) SNP in TRPC6 (or other genetic variations in genes involved in the NF-B pathway) may be an important factor in separating the scleroderma (or HIV/ AIDS or schistosomiasis) patients who develop pulmonary hypertension from those who do not.
IPAH appears to have a heterogeneous origin involving multiple genetic, molecular, and cellular abnormalities. 2, 3, 32 SNPs in genes encoding BMPR2, 7-9 activin receptor-like kinase 1 (ALK1), 33 and serotonin transporter (5-HTT) 6 have been linked to familial PAH and IPAH. Our data also link the Ϫ254(C3 G) SNP in TRPC6 to IPAH and indicate that the heterozygous Ϫ254C/G and homozygous Ϫ254G/G genotypes are associated with the occurrence of IPAH. However, mutations or SNPs in all these genes have been found in only a small portion of IPAH patients. It seems that the abnormality in each of the genes is important by itself, but none of them is sufficient to cause the disease. Therefore, the causal and pathogenic mechanisms of IPAH may involve abnormalities in multiple genes and gene products. It may be explained by the notion of multiple-hit theory proposed by many investigators. 2, 34, 35 For instance, inheritance of mutations in TRPC6 and other genes (eg, BMPR2, 5-HTT, ALK1), followed by exposure to viral infection, 31, 36 inflammatory factors, 4,37 and anorexic drugs or anorexigens, 38 results in pathogenic changes in the pulmonary vasculature and the development of IPAH.
Conclusions
We have identified a unique genetic variation, the Ϫ254(C3 G) SNP in TRPC6, which may link the inflammatory response to upregulation of TRPC6, aberrant regulation of cytoplasmic Ca 2ϩ in PASMCs, and ultimately alterations in the pulmonary vasculature. The enhanced transcriptional regulation of TRPC6 and augmented function of TRPC6 channels resulting from the Ϫ254(C3 G) SNP may predispose individuals who have this mutation to an increased risk of developing IPAH.
CLINICAL PERSPECTIVE
Genetic modifications of key genes have been associated with increased pulmonary vascular remodeling and incidence of disease in idiopathic pulmonary arterial hypertension (IPAH). We previously reported that upregulation of canonical transient receptor potential 6 (TRPC6) may be responsible for the abnormal pulmonary artery smooth muscle cell proliferation and pulmonary vascular medial hypertrophy in IPAH patients. This study identifies a gain-in-function single-nucleotide polymorphism (SNP) in the TRPC6 promoter Ϫ254(C3 G) with a significantly higher allele frequency in IPAH patients from the USA and Germany. This Ϫ254(C3 G) variation generates a functional binding site for nuclear factor-B, which results in regulation of TRPC6 expression and function in modulating cytosolic Ca 2ϩ levels in pulmonary artery smooth muscle cells. Examination of isolated pulmonary artery smooth muscle cells from IPAH patients further confirms that the presence of the Ϫ254(C3 G) single-nucleotide polymorphism is linked to TRPC6 expression and function. These findings provide a strong putative link between the inflammatory response (or activated nuclear factor-B), which has been suggested in part to underlie IPAH, and altered TRPC6 channel function, providing an alternative therapeutic strategy to treat IPAH patients and to prevent the occurrence of IPAH. PCR amplification of genomic DNA encoding the putative TRPC6 promoter region was performed by a GeneAmp PCR System (Perkin Elmer) using a Platinum PCR Supermix Kit (Invitrogen). The PCR products were detected by agarose gel electrophoresis, purified with a Gel extraction kit (Qiagen), and sequenced. The sequencing data were analyzed by Chromas software and compared with known SNPs deposited in the NCBI SNP databank. Vertebrate transcription factor binding sites within the 5'-regulatory region of human TRPC6 were identified by Dragon TF association miner (http://research.i2r.a-star.edu.sg/DRAGON/TFAM/v1.html). * Nucleotide locations related to the 5'-upstream of the translational start site (ATG). The fidelity and specificity of the primer oligonucleotides were examined using the BLAST program. Immunofluorescence staining. PASMCs on cover slips were fixed in 4% paraformaldehyde/ PBS, permeabilized and exposed to rabbit anti-TRPC6 antibody (Chemicon). FITC-conjugated goat anti-rabbit IgG was used to detect TRPC6. HA epitope tag was stained by TRITCconjugated anti-HA mouse antibody. The cells on cover slips were visualized using a confocal laser scanning microscope (LSM510 META, Zeiss).
Supplementary
Generation of recombinant adenovirus carrying human IκBαSR. The IκBα-super repressor (mutant IκBα, IκBSR) cDNA (S32A/S36A) was cloned into the pShuttle by digesting the pCMV-IκBαM with BamHI/HindIII and ligating the resulting fragments into the Xba1 site of the pShuttle vector. The pAdeno-X/IκBSR (Ad-IκB) was constructed by digesting pShuttle constructs with PI-SceI/I-CeuI and ligating the resulting fragments into the PI-SceI/I-CeuI sites of the pAdeno-X adenoviral vector. Recombinant adenoviral plasmids were packaged into infectious adenoviral particles by transfecting HEK-293 cells using LipofectAMINE PLUS reagent. The adenoviral particles were propagated in HEK-293 cells and purified on CsCl ultracentrifugation. Titers of the adenoviral stock were determined by standard plaque assay. Recombinant adenoviruses were screened for expression of the introduced gene by Western blot. pAdeno-X, which was the recombinant replication-incompetent adenovirus carrying no IκBSR cDNA insert, was used as a control adenovirus (Ad-null).
Generation of recombinant adenovirus carrying human TRPC6 specific siRNA. Recombinant adenovirus carrying siRNA targeting on human TRPC6 was generated using an Invitrogen Expression Kit. We also constructed DNA-based vector (pSilencer 2.0-U6-TRPC6) that expressed TRPC6 siRNA targeting on AAGGTCTTTATGCAATTGCTG (nucleotide 2214-2234 of TRPC6 mRNA, NM_004621). The siRNA expression DNA cassettes, including RNA Polymerase III promoter U6, a hairpin siRNA target sequence and terminator, were subcloned into pENTR1A entry vector (Invitrogen). A scrambled control vector and GAPDH specific siRNA vector were also constructed. After efficient recombination of the entry vector into the promoterless pAd/PL-DEST Gateway ® vectors, followed by viral production and transduction. The adenoviral particles for TRPC6-siRNA, GAPDH-siRNA and scramble control were plaquepurified and amplified in 293A cells. The titer of the adenoviral stock was measured by spectrophotometer. For adenovirus infection experiments, cells were infected with the appropriate virus in SMBM containing 0.2% FBS for 4 hrs and used for experiments 24 to 48 hours after adenoviral infection. ] cyt in each condition was determined as the average from 10 to 20 cells, and experiments were repeated at least four times.
Electrophysiological measurements. PASMCs were cultured on cover slips and mounted in a perfusable recording chamber on a Zeiss inverted microscope immediately before use. Membrane currents and capacitance were recorded with an EPC-9 amplifier coupled to ITC16 interface using whole-cell patch-clamp technique. Patch pipettes (2-2.5 MΩ) were pulled on a Sutter electrode puller using borosilicate glass capillary tubes, and fire polished on a Narishige microforge. Na 2 and pCa 8) . Voltage ramps ranging from -100 mV to +100 mV were applied from a holding potential of 0 mV (which inactivates voltage-gated Na + and Ca 2+ channels). All experiments were performed at room temperature (24°C). The TRPC6 currents were activated by application of 100 µM OAG for 10-15 min.
The −254(G-to-C) SNP in normal subjects and IPAH patients in African Americans. In addition to Caucasian patients, the −254(C→G) SNP in the TRPC6 gene was also found in two African American IPAH patients; the frequency of the −254G allele in African American patients is also significantly higher than in African American controls. As shown in Supplementary Table 5 , the allele frequency of the −254(C→G) SNP is 18.8% in African American IPAH patients (n=8; vs. 1.3% in African American normal controls, n=38). One of the two African American IPAH patients is a homozygote (−254G/G), and the other is a heterozygote (−254C/G). These data imply that the difference is not limited in Caucasians. 
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Differential regulation of NF-κB expression in −254C/G and −254C/C IPAH patient PASMC.
We have isolated PASMC from 4 IPAH patients, three of whom have a −254C/G genotype and one has the −254C/C genotype. Despite strenuous efforts, we have been unable to get tissue from a −254G/G allele patient prior to publication of the current study. Patient demographics and hemodynamics are reported in Supplement Table 6 . Our observations imply that TRPC6 is upregulated in PASMC from all IPAH patients, however, NF-κB only upregulates TRPC6 expression in PASMC from patients who have a −254G allele. Using PASMC from −254C/G and −254C/C individuals, we examined the regulation of TRPC6 expression by TNF-α. In the presence of TNF-α, the protein expression level of TRPC6 was not significantly different in the −254C/C IPAH PASMC infected with control adenovirus (Ad-null) and IκBα super-repressor (Ad-IκB), a nondegradable mutant dominant-negative IκBα variant that inhibits NF-κB activation and/or nuclear translocation of p65 and p50 (Supplementary Figure 1) . However, in the −254C/G IPAH PASMC, the TRPC6 protein level was significantly reduced by IκBα super-repressor (Ad-IκB). These results suggest that NF-κB-mediated TRPC6 upregulation only occurs in PASMC from −254G allele patients. Figure 1 . The −254G allele regulates NF-κB-mediated protein TRPC6 upregulation.
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